MeSH term
Frequency | Condition_Probility | Adult | 21 | 0.0 |
Comparative Study | 14 | 0.0 |
Humans | 126 | 0.0 |
Animals | 46 | 0.0 |
DNA Damage | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Cells, Cultured | 13 | 0.0 |
Cyclic AMP/metabolism | 11 | 2.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Genotype | 25 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Male | 39 | 0.0 |
Mutation/*genetics | 3 | 0.0 |
Receptors, Melanocortin | 67 | 68.0 |
Research Support, Non-U.S. Gov't | 87 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 36 | 0.0 |
Skin Neoplasms/*genetics | 8 | 6.0 |
alpha-MSH/metabolism/pharmacology | 2 | 50.0 |
Genes, p16 | 2 | 2.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
Germ-Line Mutation | 4 | 1.0 |
Melanoma/*genetics | 9 | 6.0 |
Phenotype | 20 | 0.0 |
*Proto-Oncogene Proteins | 5 | 0.0 |
Receptors, Corticotropin/genetics | 4 | 33.0 |
Risk | 2 | 0.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
Female | 36 | 0.0 |
Gene Frequency | 14 | 0.0 |
Hair Color/*genetics | 16 | 57.0 |
Heterozygote | 8 | 0.0 |
Homozygote | 8 | 0.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Receptors, Corticotropin/*genetics | 26 | 54.0 |
Variation (Genetics)/*genetics | 5 | 2.0 |
Gene Dosage | 5 | 1.0 |
Genetics, Population | 4 | 1.0 |
Receptor, Melanocortin, Type 1/*genetics | 13 | 86.0 |
Skin Pigmentation/*genetics | 14 | 66.0 |
Sunlight/adverse effects | 2 | 10.0 |
*Ultraviolet Rays | 3 | 1.0 |
*Intercellular Signaling Peptides and Proteins | 10 | 1.0 |
Mice | 20 | 0.0 |
Pigmentation/*genetics/physiology | 2 | 100.0 |
*Receptor, Melanocortin, Type 3 | 4 | 57.0 |
Skin/metabolism | 2 | 1.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Eye Color/genetics | 3 | 33.0 |
Gene Frequency/genetics | 6 | 1.0 |
Hair Color/genetics | 7 | 38.0 |
Odds Ratio | 3 | 0.0 |
Pigmentation/*genetics | 6 | 54.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Skin Pigmentation/genetics | 9 | 56.0 |
Receptors, Corticotropin/physiology | 2 | 25.0 |
Signal Transduction | 5 | 0.0 |
alpha-MSH/*analogs & derivatives/*pharmacology | 2 | 50.0 |
Amino Acid Sequence | 25 | 0.0 |
Base Sequence | 21 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
Haplotypes | 4 | 0.0 |
Hela Cells | 2 | 0.0 |
Melanocytes/cytology/metabolism | 2 | 20.0 |
Molecular Sequence Data | 34 | 0.0 |
Polymorphism, Genetic | 11 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
DNA/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Melanins/metabolism | 6 | 26.0 |
Melanocytes/metabolism | 5 | 12.0 |
Pigmentation | 3 | 21.0 |
Sunlight | 3 | 23.0 |
Time Factors | 2 | 0.0 |
Transfection | 11 | 0.0 |
Transgenes | 2 | 0.0 |
Ultraviolet Rays | 8 | 1.0 |
Aged | 13 | 0.0 |
Case-Control Studies | 11 | 0.0 |
Environmental Exposure | 2 | 1.0 |
Middle Aged | 15 | 0.0 |
Monophenol Monooxygenase/*genetics | 2 | 8.0 |
Receptors, Calcitriol/genetics | 3 | 6.0 |
Risk Factors | 13 | 0.0 |
Ultraviolet Rays/*adverse effects | 5 | 10.0 |
Cell Line | 12 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Models, Molecular | 8 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Skin/chemistry | 3 | 8.0 |
Structure-Activity Relationship | 10 | 0.0 |
Alleles | 26 | 0.0 |
*Mutation | 3 | 0.0 |
Protein Binding | 6 | 0.0 |
*Variation (Genetics) | 7 | 0.0 |
*Alleles | 2 | 0.0 |
Mutation | 7 | 0.0 |
Variation (Genetics) | 16 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
DNA/genetics | 4 | 0.0 |
English Abstract | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
DNA Primers | 7 | 0.0 |
*Polymorphism, Genetic | 10 | 0.0 |
Prognosis | 2 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Melanoma/epidemiology/*genetics | 7 | 46.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Skin Neoplasms/epidemiology/*genetics | 4 | 28.0 |
Age of Onset | 2 | 0.0 |
DNA Mutational Analysis | 8 | 0.0 |
Pedigree | 6 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Variation (Genetics)/genetics | 3 | 1.0 |
Adolescent | 4 | 0.0 |
Child | 3 | 0.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Hair Color | 4 | 80.0 |
Melanoma/etiology/*genetics | 3 | 33.0 |
Receptors, Corticotropin/*genetics/physiology | 3 | 100.0 |
Skin Neoplasms/etiology/*genetics | 2 | 33.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Binding Sites | 4 | 0.0 |
Phylogeny | 4 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Receptors, Corticotropin/*genetics/metabolism | 5 | 55.0 |
Ligands | 10 | 0.0 |
Protein Conformation | 6 | 0.0 |
Carcinoma, Basal Cell/*genetics | 2 | 14.0 |
*Genetic Predisposition to Disease | 7 | 0.0 |
China/ethnology | 2 | 1.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Models, Genetic | 4 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Receptors, Corticotropin/*metabolism | 4 | 44.0 |
alpha-MSH/metabolism | 7 | 46.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Pigmentation/*physiology | 4 | 66.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
MSH/metabolism | 3 | 50.0 |
Point Mutation | 5 | 0.0 |
Receptors, Pituitary Hormone/*genetics | 8 | 61.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Species Specificity | 3 | 0.0 |
Sunburn/genetics | 2 | 100.0 |
Ireland | 2 | 3.0 |
Africa | 2 | 2.0 |
Europe | 2 | 0.0 |
*Selection (Genetics) | 2 | 3.0 |
Cyclin-Dependent Kinases/genetics | 2 | 3.0 |
Genes, p16/*genetics | 2 | 4.0 |
Child, Preschool | 2 | 0.0 |
Cyclin-Dependent Kinases/*genetics | 2 | 3.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Skin/pathology | 2 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Receptor, Melanocortin, Type 4 | 2 | 2.0 |
Chickens/*genetics | 2 | 2.0 |
Chromosome Mapping | 5 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
DNA Probes | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Horses/*genetics | 2 | 9.0 |
HLA-A2 Antigen/*immunology | 2 | 9.0 |
COS Cells | 3 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Receptor, Melanocortin, Type 1/analysis | 2 | 100.0 |
alpha-MSH/analogs & derivatives/metabolism | 2 | 66.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Immunohistochemistry | 3 | 0.0 |
Cyclic AMP/analysis | 2 | 8.0 |
alpha-MSH/*analogs & derivatives/metabolism | 2 | 66.0 |
Iodine Radioisotopes | 3 | 0.0 |
*Oxidoreductases | 2 | 2.0 |
Pigmentation/physiology | 2 | 40.0 |
MSH/pharmacology | 2 | 33.0 |
Mice, Mutant Strains | 2 | 0.0 |
Cattle | 2 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Melanins/*biosynthesis | 2 | 12.0 |
Melanocytes/*metabolism | 2 | 5.0 |
Monophenol Monooxygenase/metabolism | 2 | 10.0 |
Kinetics | 4 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Receptor, Melanocortin, Type 1/*genetics/physiology | 2 | 100.0 |
Receptors, Melanocortin/*genetics | 2 | 100.0 |
*Synteny | 2 | 20.0 |
Drug Design | 3 | 0.0 |
Receptor, Melanocortin, Type 1/genetics/metabolism | 2 | 100.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Melanoma/metabolism | 2 | 7.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Receptors, Corticotropin/genetics/*metabolism | 3 | 30.0 |
Sequence Alignment | 2 | 0.0 |
Arginine/chemistry | 4 | 6.0 |
Tryptophan/chemistry | 3 | 7.0 |
Twins, Dizygotic | 2 | 5.0 |
Twins, Monozygotic | 2 | 2.0 |
Cystine/chemistry | 2 | 18.0 |
Receptors, Corticotropin/*biosynthesis/*genetics | 2 | 100.0 |
